Sensus Healthcare Inc. reported revenues of $6.9 million for the third quarter of 2025. The company recorded a net loss of $0.9 million, or $0.06 per share, for the quarter. For the first nine months of 2025, revenues were $22.5 million, down 21.6% from $28.7 million in the same period of 2024. Net loss for the nine-month period was $4.6 million, or $0.28 per share, compared to net income of $5.1 million, or $0.31 per diluted share, in the first nine months of 2024. Sensus shipped 16 SRT systems in the third quarter, including 10 to a large customer and three internationally, bringing total units sold for the nine months to 56, compared to 76 in the same period last year. The company exited the quarter with $24.5 million in cash and no debt. CMS established coding validating SRT for treating non-melanoma skin cancer during the period. The Fair Deal Agreement treatment volume increased by 20% over the previous quarter. Research and development expenses rose to $5.9 million for the first nine months of 2025, primarily due to lobbying costs, higher headcount, and product development. Cost of sales for the nine months was $12.6 million, up from $11.4 million in the same period of 2024.